Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Engerix B Pediatric + diphtheria-tetanus-pertussis vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Oral
01
Overview
This entry refers to the concomitant administration of **Engerix B Pediatric** (a recombinant hepatitis B vaccine) and a multivalent vaccine containing **diphtheria, tetanus, and pertussis** antigens (such as Sanofi's CombAct-HIB). In the context of pediatric immunization programs and clinical trials sponsored by Sanofi Pasteur, this regimen often includes additional components such as *Haemophilus influenzae* type b (Hib) and poliovirus vaccines (e.g., OPV). Engerix B Pediatric, developed by GSK, is a non-infectious recombinant DNA vaccine containing purified hepatitis B surface antigen (HBsAg) produced in yeast cells. The DTP component typically consists of diphtheria and tetanus toxoids along with acellular pertussis antigens. This combination is used to provide active immunity against multiple childhood infectious diseases and frequently serves as a standard-of-care comparator in the development of hexavalent vaccines.
- Brand names
- Engerix B PediatricCombAct-HIB
- Other names
- Engerix B Pediatric-Sanofi Pasteur, a Sanofi Company-diphtheria-tetanus-pertussisEngerix B Pediatric + DTaP-Hib + OPV
02
Targets
FIM2/FIM3 (Fimbriae types 2 and 3)Poliovirus type 1 D-antigenPoliovirus type 3 D-antigenPRN (Pertactin)Diphtheria toxinHBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on Engerix B Pediatric + diphtheria-tetanus-pertussis vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Engerix B Pediatric + diphtheria-tetanus-pertussis vaccine.